AKURAT.CO, The World Health Organization (WHO) issued an emergency use permit for the polio nOPV2 vaccine, one of which was produced by the BUMN Pharmacy Holding of PT Bio Farma, Friday (11/13/2020).
“WHO today included the nOPV2 vaccine (Bio Farma, Indonesia) in the list of emergency uses to deal with the high number of positive cases of polio in a number of African and Eastern Mediterranean countries. The western Pacific and Southeast Asia regions are also affected by this outbreak,” WHO said. through his written broadcast, as reported by Antara, Sunday (11/15/2020).
For the first time, WHO has issued an emergency use permit (EUL) for vaccines. Therefore, WHO hopes that this step can also be applied to the COVID-19 vaccine candidate.
The nOPV2 vaccine is a new type of anti-polio virus (cVDPVs) developed by a global collaborative network of institutions and experts from various countries, the Global Initiative to Eradicate Polio (GPEI).
The collaborative network is joined by Bio Farma, a state-owned company that produces vaccines in Indonesia; University of Antwerp in Belgium; non-governmental organization Against Infectious Diseases in Developing Countries (FIDEC); The National Institute for Biological Standards and Control (NIBSC) in the UK; University of California San Francisco (UCSF), United States; Centers for Disease Control and Prevention (CDC), USA; and various other non-governmental organizations such as PATH and the Bill & Melinda Gates Foundation.
also read:
In the last 30 years, efforts to eliminate polio cases have reached 99.9 percent. However, these efforts have not yet reached the end because the polio virus cVDPVs are still frequently spread in populations that rarely have access to immunizations.
“If many children do not get polio immunization, the virus can be passed between individuals and between generations so that the virus forms a new strain that can cause paralysis. Type two cVDPVs virus is the type that is quite common today,” explained WHO.
For information, previously, WHO introduced a procedure for applying for an emergency use permit (EUL) when Ebola broke out in West Africa in 2014-2016. There are at least three main stages that a vaccine candidate must go through to obtain an emergency use permit.
This stage includes the preparation phase, the emergency phase, and the phase after entering the emergency use permit list. WHO will invite a team of independent experts to examine vaccine candidates and various available phase II and III clinical trial data, as well as set up a surveillance system and design further research.[]
–
